Clinical use of frataxin measurement in a patient with a novel deletion in the FXN gene

Francesco Saccà, Angela Marsili, Giorgia Puorro, Antonella Antenora, Chiara Pane, Alessandra Tessa, Pasquale Scoppettuolo, Claudia Nesti, Vincenzo Brescia Morra, Giuseppe De Michele, Filippo M. Santorelli, Alessandro Filla

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Friedreich ataxia (FRDA) is caused by a GAA expansion in the first intron of the FXN gene, which encodes frataxin. Four percent of patients harbor a point mutation on one allele and a GAA expansion on the other. We studied an Italian patient presenting with symptoms suggestive of FRDA, and carrying a single expanded 850 GAA allele. As a second diagnostic step, frataxin was measured in peripheral blood mononuclear cells, and proved to be in the pathological range (2.95 pg/μg total protein, 12.7 % of control levels). Subsequent sequencing revealed a novel deletion in exon 5a (c.572delC) which predicted a frameshift at codon 191 and a premature truncation of the protein at codon 194 (p.T191IfsX194). FXN/mRNA expression was reduced to 69.2 % of control levels. Clinical phenotype was atypical with absent dysarthria, and rapid disease progression. l-Buthionine-sulphoximine treatment of the proband's lymphoblasts showed a severe phenotype as compared to classic FRDA.

Original languageEnglish
Pages (from-to)1116-1121
Number of pages6
JournalJournal of Neurology
Volume260
Issue number4
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Friedreich Ataxia
Codon
Alleles
Genes
Buthionine Sulfoximine
Phenotype
Dysarthria
Point Mutation
Introns
Disease Progression
Exons
Blood Cells
Proteins
Messenger RNA
frataxin
Therapeutics

Keywords

  • BSO
  • Deletion
  • Friedreich ataxia
  • l-Buthionine-sulphoximine
  • Lymphoblastoid
  • qPCR

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Saccà, F., Marsili, A., Puorro, G., Antenora, A., Pane, C., Tessa, A., ... Filla, A. (2013). Clinical use of frataxin measurement in a patient with a novel deletion in the FXN gene. Journal of Neurology, 260(4), 1116-1121. https://doi.org/10.1007/s00415-012-6770-5

Clinical use of frataxin measurement in a patient with a novel deletion in the FXN gene. / Saccà, Francesco; Marsili, Angela; Puorro, Giorgia; Antenora, Antonella; Pane, Chiara; Tessa, Alessandra; Scoppettuolo, Pasquale; Nesti, Claudia; Brescia Morra, Vincenzo; De Michele, Giuseppe; Santorelli, Filippo M.; Filla, Alessandro.

In: Journal of Neurology, Vol. 260, No. 4, 04.2013, p. 1116-1121.

Research output: Contribution to journalArticle

Saccà, F, Marsili, A, Puorro, G, Antenora, A, Pane, C, Tessa, A, Scoppettuolo, P, Nesti, C, Brescia Morra, V, De Michele, G, Santorelli, FM & Filla, A 2013, 'Clinical use of frataxin measurement in a patient with a novel deletion in the FXN gene', Journal of Neurology, vol. 260, no. 4, pp. 1116-1121. https://doi.org/10.1007/s00415-012-6770-5
Saccà, Francesco ; Marsili, Angela ; Puorro, Giorgia ; Antenora, Antonella ; Pane, Chiara ; Tessa, Alessandra ; Scoppettuolo, Pasquale ; Nesti, Claudia ; Brescia Morra, Vincenzo ; De Michele, Giuseppe ; Santorelli, Filippo M. ; Filla, Alessandro. / Clinical use of frataxin measurement in a patient with a novel deletion in the FXN gene. In: Journal of Neurology. 2013 ; Vol. 260, No. 4. pp. 1116-1121.
@article{5543af732b2b4eb3b6669d2ec1d2f8a7,
title = "Clinical use of frataxin measurement in a patient with a novel deletion in the FXN gene",
abstract = "Friedreich ataxia (FRDA) is caused by a GAA expansion in the first intron of the FXN gene, which encodes frataxin. Four percent of patients harbor a point mutation on one allele and a GAA expansion on the other. We studied an Italian patient presenting with symptoms suggestive of FRDA, and carrying a single expanded 850 GAA allele. As a second diagnostic step, frataxin was measured in peripheral blood mononuclear cells, and proved to be in the pathological range (2.95 pg/μg total protein, 12.7 {\%} of control levels). Subsequent sequencing revealed a novel deletion in exon 5a (c.572delC) which predicted a frameshift at codon 191 and a premature truncation of the protein at codon 194 (p.T191IfsX194). FXN/mRNA expression was reduced to 69.2 {\%} of control levels. Clinical phenotype was atypical with absent dysarthria, and rapid disease progression. l-Buthionine-sulphoximine treatment of the proband's lymphoblasts showed a severe phenotype as compared to classic FRDA.",
keywords = "BSO, Deletion, Friedreich ataxia, l-Buthionine-sulphoximine, Lymphoblastoid, qPCR",
author = "Francesco Sacc{\`a} and Angela Marsili and Giorgia Puorro and Antonella Antenora and Chiara Pane and Alessandra Tessa and Pasquale Scoppettuolo and Claudia Nesti and {Brescia Morra}, Vincenzo and {De Michele}, Giuseppe and Santorelli, {Filippo M.} and Alessandro Filla",
year = "2013",
month = "4",
doi = "10.1007/s00415-012-6770-5",
language = "English",
volume = "260",
pages = "1116--1121",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "4",

}

TY - JOUR

T1 - Clinical use of frataxin measurement in a patient with a novel deletion in the FXN gene

AU - Saccà, Francesco

AU - Marsili, Angela

AU - Puorro, Giorgia

AU - Antenora, Antonella

AU - Pane, Chiara

AU - Tessa, Alessandra

AU - Scoppettuolo, Pasquale

AU - Nesti, Claudia

AU - Brescia Morra, Vincenzo

AU - De Michele, Giuseppe

AU - Santorelli, Filippo M.

AU - Filla, Alessandro

PY - 2013/4

Y1 - 2013/4

N2 - Friedreich ataxia (FRDA) is caused by a GAA expansion in the first intron of the FXN gene, which encodes frataxin. Four percent of patients harbor a point mutation on one allele and a GAA expansion on the other. We studied an Italian patient presenting with symptoms suggestive of FRDA, and carrying a single expanded 850 GAA allele. As a second diagnostic step, frataxin was measured in peripheral blood mononuclear cells, and proved to be in the pathological range (2.95 pg/μg total protein, 12.7 % of control levels). Subsequent sequencing revealed a novel deletion in exon 5a (c.572delC) which predicted a frameshift at codon 191 and a premature truncation of the protein at codon 194 (p.T191IfsX194). FXN/mRNA expression was reduced to 69.2 % of control levels. Clinical phenotype was atypical with absent dysarthria, and rapid disease progression. l-Buthionine-sulphoximine treatment of the proband's lymphoblasts showed a severe phenotype as compared to classic FRDA.

AB - Friedreich ataxia (FRDA) is caused by a GAA expansion in the first intron of the FXN gene, which encodes frataxin. Four percent of patients harbor a point mutation on one allele and a GAA expansion on the other. We studied an Italian patient presenting with symptoms suggestive of FRDA, and carrying a single expanded 850 GAA allele. As a second diagnostic step, frataxin was measured in peripheral blood mononuclear cells, and proved to be in the pathological range (2.95 pg/μg total protein, 12.7 % of control levels). Subsequent sequencing revealed a novel deletion in exon 5a (c.572delC) which predicted a frameshift at codon 191 and a premature truncation of the protein at codon 194 (p.T191IfsX194). FXN/mRNA expression was reduced to 69.2 % of control levels. Clinical phenotype was atypical with absent dysarthria, and rapid disease progression. l-Buthionine-sulphoximine treatment of the proband's lymphoblasts showed a severe phenotype as compared to classic FRDA.

KW - BSO

KW - Deletion

KW - Friedreich ataxia

KW - l-Buthionine-sulphoximine

KW - Lymphoblastoid

KW - qPCR

UR - http://www.scopus.com/inward/record.url?scp=84876466474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876466474&partnerID=8YFLogxK

U2 - 10.1007/s00415-012-6770-5

DO - 10.1007/s00415-012-6770-5

M3 - Article

VL - 260

SP - 1116

EP - 1121

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 4

ER -